IGF1 Signaling Pathway and Insig2 as A Drug Target (G51141)

Target Name: INSIG2

NCBI ID: G51141

INSIG2

IGF1 Signaling Pathway and Insig2 as A Drug Target

The insulin-like growth factor (IGF) signaling pathway is a critical signaling pathway that regulates cellular growth, differentiation, and survival. Mutations in the IGF1 receptor have been linked to a variety of human diseases, including obesity, diabetes, and cancer. The insulin-like growth factor receptor (IGFR) is a protein that plays a crucial role in this pathway.Insig2 (INSI2_HUMAN) is a protein that has been identified as a potential drug target or biomarker for a variety of diseases.

IGF signaling is a complex process that involves the interaction of multiple proteins. The IGF1 receptor is a key component of this pathway. It is a transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The IGF1 receptor is involved in regulating cellular growth, differentiation, and survival by activating theInsig2 signaling pathway.

Insig2 is a protein that is expressed in a variety of tissues and cells, including muscle, bone, and cancer cells. It is a 21-kDa protein that consists of an N-terminus, a catalytic domain, and a C-terminus. Insig2 functions as a negative regulator of the IGF1 receptor by binding to its intracellular domain and preventing it from activating the signaling pathway.

Insig2 has been shown to play a role in a variety of diseases, including obesity, diabetes, and cancer. It has been shown to be involved in the regulation of cellular processes that are critical for disease development, including metabolism, inflammation, and stress resistance.

In obesity

Obesity is a serious public health issue that is characterized by excess body weight and a lack of physical activity. It is a condition that is associated with a range of health problems, including cardiovascular disease, diabetes, and certain cancers. Insig2 has been shown to be involved in the regulation of obesity by interacting with the IGF1 receptor and contributing to the development of this condition.

Research has shown that Insig2 is involved in the regulation of metabolism by activating the PI3K/Akt signaling pathway. This pathway is involved in the regulation of energy metabolism and is a key player in the development of obesity. Insig2 has been shown to increase the activity of the PI3K/Akt signaling pathway, which can lead to an increase in the production of reactive oxygen species (ROS) and a reduction in the levels of antioxidants that protect cells from damage.

Insig2 has also been shown to contribute to the regulation of inflammation by activating the NF-kappa-B signaling pathway. This pathway is involved in the regulation of immune and inflammatory responses and is a key player in the development of obesity. Insig2 has been shown to increase the activity of the NF-kappa-B signaling pathway, which can lead to an increase in the production of pro-inflammatory cytokines and a reduction in the levels of anti-inflammatory cytokines.

Insig2 has also been shown to contribute to the regulation of stress resistance by activating the ERK signaling pathway. This pathway is involved in the regulation of cell stress responses and is a key player in the development of obesity. Insig2 has been shown to increase the activity of the ERK signaling pathway, which can lead to an increase in the production of reactive oxygen species (ROS) and a reduction in the levels of antioxidants that protect cells from damage.

In diabetes

Diabetes is a serious public health issue that is characterized by the absence of insulin and an increased risk of the development of cardiovascular disease and certain cancers. Insig2 has been shown to be involved in the regulation of diabetes by interacting with the IGF1 receptor and contributing to the development of this condition.

Research has shown that Insig2 is involved in the regulation of insulin sensitivity by activating the

Protein Name: Insulin Induced Gene 2

Functions: Oxysterol-binding protein that mediates feedback control of cholesterol synthesis by controlling both endoplasmic reticulum to Golgi transport of SCAP and degradation of HMGCR (PubMed:12242332, PubMed:16606821, PubMed:32322062). Acts as a negative regulator of cholesterol biosynthesis by mediating the retention of the SCAP-SREBP complex in the endoplasmic reticulum, thereby blocking the processing of sterol regulatory element-binding proteins (SREBPs) SREBF1/SREBP1 and SREBF2/SREBP2 (PubMed:32322062). Binds oxysterol, including 22-hydroxycholesterol, 24-hydroxycholesterol, 25-hydroxycholesterol and 27-hydroxycholesterol, regulating interaction with SCAP and retention of the SCAP-SREBP complex in the endoplasmic reticulum (PubMed:26160948, PubMed:17428920, PubMed:32322062). In presence of oxysterol, interacts with SCAP, retaining the SCAP-SREBP complex in the endoplasmic reticulum, thereby preventing SCAP from escorting SREBF1/SREBP1 and SREBF2/SREBP2 to the Golgi (PubMed:32322062). Sterol deprivation or phosphorylation by PCK1 reduce oxysterol-binding, disrupting the interaction between INSIG2 and SCAP, thereby promoting Golgi transport of the SCAP-SREBP complex, followed by processing and nuclear translocation of SREBF1/SREBP1 and SREBF2/SREBP2 (PubMed:32322062). Also regulates cholesterol synthesis by regulating degradation of HMGCR: initiates the sterol-mediated ubiquitin-mediated endoplasmic reticulum-associated degradation (ERAD) of HMGCR via recruitment of the reductase to the ubiquitin ligase RNF139 (PubMed:16606821, PubMed:22143767)

The "INSIG2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INSIG2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets